Literature DB >> 34788199

Measles vaccination of special risk groups.

Vassiliki Papaevangelou1.   

Abstract

Measles is an important vaccine preventable disease with significant morbidity and mortality. Although measles vaccine is a safe and effective vaccine available worldwide for more than 50 years, still immunization efforts have not successfully reached the WHO goal of 95% vaccination coverage. Hesitancy is especially increased amongst parents of children with chronic conditions. Contraindications for measles-containing vaccines are well defined and include history of anaphylactic reactions to neomycin, history of severe allergic reaction to previous vaccination, pregnancy, and severe immunosuppression. Concurrently, precautions for measles-containing vaccines include amongst other, history of thrombocytopenia or thrombocytopenic purpura and personal or family history of seizures of any etiology. This article aims to address misconceptions on measles vaccine safety and review data on adverse events among special groups of subjects at increased risk following measles immunization.

Entities:  

Keywords:  Measles; allergies; contraindications; immunization; immunosuppression; misconceptions; precautions; seizures

Mesh:

Substances:

Year:  2021        PMID: 34788199      PMCID: PMC8903983          DOI: 10.1080/21645515.2021.1997034

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  24 in total

Review 1.  Barriers to the vaccination of children and adolescents and possible solutions.

Authors:  S Esposito; N Principi; G Cornaglia
Journal:  Clin Microbiol Infect       Date:  2014-01-24       Impact factor: 8.067

2.  Response to measles-mumps-rubella vaccine in children on dialysis.

Authors:  S L Schulman; A Deforest; B A Kaiser; M S Polinsky; H J Baluarte
Journal:  Pediatr Nephrol       Date:  1992-03       Impact factor: 3.714

3.  Determinants of low measles vaccination coverage in children living in an endemic area.

Authors:  Andrea Lo Vecchio; Maria Donata Cambriglia; Maria Cristina Fedele; Francesca Wanda Basile; Fabrizia Chiatto; Michele Miraglia Del Giudice; Alfredo Guarino
Journal:  Eur J Pediatr       Date:  2018-11-14       Impact factor: 3.183

4.  Effects of measles-containing vaccination in children with severe underlying neurologic disease.

Authors:  Dimitra Dimopoulou; Maria Koutsaki; Melpomeni Giorgi; Maria Spanou; Argirios Dinopoulos; Vassiliki Papaevangelou
Journal:  Vaccine       Date:  2020-12-03       Impact factor: 3.641

Review 5.  Vaccinations in pediatric kidney transplant recipients.

Authors:  Thomas G Fox; Corina Nailescu
Journal:  Pediatr Nephrol       Date:  2018-04-18       Impact factor: 3.714

Review 6.  Adverse events following immunization: real causality and myths.

Authors:  Nicola Principi; Susanna Esposito
Journal:  Expert Opin Drug Saf       Date:  2016-04-01       Impact factor: 4.250

Review 7.  Vaccine administration in children with chronic kidney disease.

Authors:  Susanna Esposito; Maria Vincenza Mastrolia; Elisabetta Prada; Carlo Pietrasanta; Nicola Principi
Journal:  Vaccine       Date:  2014-11-20       Impact factor: 3.641

Review 8.  Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports.

Authors:  Evelina Croce; Christoph Hatz; Emile F Jonker; L G Visser; Veronika K Jaeger; Silja Bühler
Journal:  Vaccine       Date:  2017-02-03       Impact factor: 3.641

9.  Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation.

Authors:  K Pauksen; V Duraj; P Ljungman; J Sjölin; G Oberg; G Lönnerholm; E Fridell; B Smedmyr; B Simonsson
Journal:  Bone Marrow Transplant       Date:  1992-06       Impact factor: 5.483

10.  Risk of seizures after measles-mumps-rubella immunization.

Authors:  M R Griffin; W A Ray; E A Mortimer; G M Fenichel; W Schaffner
Journal:  Pediatrics       Date:  1991-11       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.